Cytokinetics Incorporated has transitioned from a research-focused stage to active commercialization following the December 2025 FDA approval of MYQORZO (aficamten) for obstructive hypertrophic cardiomyopathy. Sales began in early 2026 with European regulatory approvals supporting expansion outside the US. Strategic licensing partnerships with Bayer and Sanofi target Asian markets. Despite this milestone, Cytokinetics faces significant financial pressures from sustained net losses, heavy cash burn, and over $1.3 billion in borrowings including convertible notes and term loans. Liquidity remains a focal point as the company balances capital allocation toward commercial infrastructure while advancing pipeline clinical programs.